Alia Therapeutics
MILAN, ITALY / ACCESSWIRE / May 9, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Adel Nada as an independent member of the Board of Directors.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Adel Nada is Co-founder and Chief Executive Officer of GentiBio, a biotherapeutics company that is developing engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics, where he worked on advancing engineered regulatory T cell therapeutics.
Over the past 15 years, he has successfully led translational and immunology programs for experimental and approved therapies, spanning small and large molecules, as well as engineered immune cell products.
Paola Pozzi, Partner at Sofinnova Partners and a member of Alia's Board of Directors, said: "Adel's experience and knowledge of the field will help guide Alia towards the next stage in its development. We feel very fortunate to have such an esteemed leader join our Board of Directors."
Adel Nada, Independent Board Director of Alia, said: "I'm delighted to have been invited to join the board of such a compelling biotech with a very differentiated genome editing platform. I look forward to advancing Alia's platforms and pipeline to enable novel, tailored gene editing strategies that have the potential to overcome current limitations of genome editing and bring more therapies to patients with underserved and currently untreatable diseases and conditions."
Letizia Goretti, Chief Executive Officer of Alia, said: "Adel's experience in biotech is both broad and deep. We are really excited to partner with him as Alia's growth accelerates."
Adel received his medical degree from Alexandria University in Egypt and his master's degree in clinical research from the Pharmacology Dept. at Rush University in Chicago, where he also held an academic position and practiced for 10 years in affiliated hospitals.
About Alia Therapeutics
Alia Therapeutics is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. The company was founded in October 2018 by Anna Cereseto and a group of researchers from CIBIO, the biotech department of the University of Trento, who discovered the core CRISPR technologies exploited by the start-up. Read more at aliatherapeutics.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
For more information about Sofinnova Telethon, visit https://sofinnovapartners.com/strategy/telethon
Contact
Letizia Goretti
CEO, Alia Therapeutics
info@aliatx.com
SOURCE: Alia Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/753506/Alia-Therapeutics-appoints-Adel-Nada-as-Independent-Board-Director
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GoodData Announces Launch of MCP Server to Let AI Execute Analytics End-to-End21.1.2026 10:00:00 CET | Press release
Combining MCP, analytics-as-code, and LLMs to automate analytics execution at software speed SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / GoodData, a leader in AI analytics and decision intelligence, today announced the public launch of its MCP Server. As organisations adopt AI in analytics, most tools remain limited to query generation, leaving teams to manually manage metrics, dashboards and business logic. MCP Server moves AI beyond analysis, enabling governed, end-to-end analytics execution and delivering 10-50x faster time to value. The MCP Server is designed for AI developers, and BI and data teams who want to build and manage analytics faster with AI. It allows AI to build and operate analytics in the same way a skilled human team would, but faster and without operational bottlenecks. Using the Model Context Protocol (MCP), AI agents and large language models (LLMs) can connect directly to GoodData and execute analytics across the full lifecycle. They can wor
Kontent.ai Launches AI-Powered SEO and GEO Workflows to Cut Optimization Time by Up to 80% and Optimize Content for Search and Answer Visibility21.1.2026 08:00:00 CET | Press release
Kontent.ai today announced the launch of new agentic SEO and Generative Engine Optimization (GEO) workflows following early results that show organizations reducing the time required to audit and optimize content performance by up to 80 percent while improving organic and answer engine reach without additional media spend. BRNO, CZ / ACCESS Newswire / January 21, 2026 / As content inventories grow into hundreds of thousands of items, search engine optimization (SEO) has become a significant operational cost. Manual audits, spreadsheet-driven updates, and disconnected tooling make it difficult for teams to keep content accurate, structured, and discoverable across both traditional search engines and AI-driven discovery platforms. Kontent.ai's new agentic workflows are designed to change that cost and effort curve. Embedded directly within the CMS, autonomous agents continuously analyze content for missing or inconsistent metadata, unclear structure, outdated terminology, and weak intern
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
Innodata Awarded Prime Contract Position on U.S. Missile Defense Agency's IDIQ SHIELD Program20.1.2026 14:30:00 CET | Press release
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2026 / INNODATA INC. (Nasdaq:INOD) today announced that it was awarded a contract for the Missile Defense Agency Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. The SHIELD program is designed to drive rapid innovation and deliver next-generation capabilities that strengthen the nation's multi-layered homeland defense architecture. As part of the broader Golden Dome strategy, this selection positions Innodata to compete for future task orders across research, development, engineering, prototyping, and operations of critical Missile Defense Agency systems that support U.S. national security objectives. The award was made as part of a list of companies eligible to compete under the program publicly announced by the U.S. Government on 15-Jan-26. "We are proud to support our nation's mission to defend the homeland," said Vinay Malkani, SVP Federal of Innodata. "This co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom